Nirmatrelvir-ritonavir (NMVr), better known as Paxlovid, the drug that has proven to be an effective treatment for COVID-19, does interact with some prescribed cardiovascular medications, meaning some should be discontinued and that alternatives to NMVr should be given when the cardiovascular medication cannot be safely interrupted, according to a new review.